ACAD — Acadia Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $4.34bn
- $3.48bn
- $1.07bn
U.S. RESEARCH ROUNDUP-Acadia Pharmaceuticals, Applovin Corp, Centuri Holdings
Acadia Phramaceuticals Q3 revenue rises, lifts 2025 revenue guidance
Brief: Acadia Pharmaceuticals Q3 EPS USD 0.42
U.S. RESEARCH ROUNDUP- AGCO, Caterpillar, United Rentals
U.S. RESEARCH ROUNDUP-Carmax, Mirion Technologies, Valmont Industries
U.S. RESEARCH ROUNDUP- Apogee Therapeutics, Intel, Northern Trust
U.S. STOCKS ON THE MOVE-Marvell, US energy companies, copper miners
Soleno Therapeutics rises after rival's rare disease drug fails late-stage study
Acadia falls as rare disease therapy fails late-stage trial
U.S. STOCKS ON THE MOVE-Thor Industries, Mirion Technologies, ServiceNow
Acadia falls as rare disease therapy fails late-stage trial
Acadia Pharmaceuticals' rare disease therapy fails late-stage trial (updated)
Brief: Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
Acadia Pharmaceuticals' rare disease drug fails main goal in late-stage trial
Brief: Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Acadia Pharmaceuticals Appoints Konstantina Katcheves As Senior Vice President, Chief Business And Strategy Officer
Live Markets: Prader-Willi drug sparks Wall Street interest in multi-billion dollar market, Leerink says
Australia's Neuren Pharmaceuticals hits one-year high on DAYBUE sales jump
Acadia Pharmaceuticals Inc Reports Results For The Quarter Ended June 30: Earnings Summary